Ajanta Pharma ties up with Biocon to target emerging markets for generic weight loss drug

Ajanta, which derives more than 40 percent of its revenue from these markets, signed an agreement with Biocon to distribute generic semaglutide in 26 countries in Asia and Africa next year due to the expiration of patents. Under the agreement, Ajanta will procure the finished product (semaglutide injectable pen) from Biocon and distribute it under its own brand name only in 23 countries and semi-exclusively in another three countries, the company’s top executive said. Mint in an interview.